{"entity":{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","aka":[],"tldr":"Co-discovered EGFR mutations in lung cancer and linked Fusobacterium to colorectal cancer.","summary":"Matthew Meyerson is Director of the Center for Cancer Genomics at Dana-Farber and an Institute Member of the Broad Institute of MIT and Harvard. He is a genomicist known for co-discovering EGFR mutations in lung cancer in 2004, mapping lung adenocarcinoma genomes for The Cancer Genome Atlas, and identifying enrichment of Fusobacterium nucleatum in colorectal tumours. His selected papers report EGFR mutations in lung cancer correlating with response to gefitinib, and the genomic analysis associating Fusobacterium with colorectal carcinoma. He continues to work on lung cancer genomics and the microbiome in cancer.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/matthew-meyerson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Genomics, Dana-Farber; Institute Member, Broad","institutionId":"broad-institute","specialisms":["Lung cancer genomics","EGFR mutations","Microbiome and cancer"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/matthew-meyerson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D"}],"papers":[{"title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","journal":"Science","year":2004,"url":"https://doi.org/10.1126/science.1099314","doi":"10.1126/science.1099314"},{"title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma","journal":"Genome Research","year":2012,"url":"https://doi.org/10.1101/gr.126573.111","doi":"10.1101/gr.126573.111"}],"orcid":"0000-0002-9133-8108"},"route":"/people/matthew-meyerson/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"institution":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/"}],"paper":[{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/"},{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/"},{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/"},{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/"}]}}